published on 01/08/2021 at 8:03 am
(Boursier.com) — Nanobiotix , a French company pioneer in nanomedicine developing new therapeutic approaches for the treatment of cancer by increasing the effectiveness of radiotherapy and the proportion of patients who respond to inhibitory checkpoints, today announces its global development plan for 2021 and beyond .
Radiation therapy, also called radiation therapy, involves the use of x-rays or other high-energy particles or rays to kill cancer cells in tumors. It is one of the most common anti-cancer treatments, as stand-alone therapy as well as in combination with surgery, chemotherapy or biotherapies. In developed countries with access to radiation therapy, about 60% of cancer patients will receive radiation therapy at least once, either alone or as part of a more complex treatment protocol. Nonetheless, many of these patients still die from the progression of their cancer because, among other reasons, they cannot receive a dose of radiation high enough to completely destroy their tumor without causing an unacceptable level of damage to surrounding healthy tissue.
Nanobiotix’s pioneering approach uses nanophysics to provide a physical mode of action to destroy cancer cells. Unlike chemotherapy or traditional biologics, NBTXR3 has a mechanism of action applicable in the treatment of all types of solid tumors in combination with radiotherapy and in combination with other anti-cancer drugs.
Nanobiotix believes that the mode of action of NBTXR3 may be of benefit in all indications of solid tumors that can be treated with radiotherapy. These patient populations represent an important commercial opportunity for NBTXR3. In addition, the Company believes that NBTXR3 could provide new opportunities for cancer patients who currently cannot be treated with radiation therapy due to radiosensitivity or other characteristics of the tissues located near the tumor.
After a successful IPO on the Nasdaq in the fourth quarter of 2020, the company has long-term goals (i) to complete the development of NBTXR3 in the treatment of locally advanced head and neck cancers and to meet regulatory requirements applicable in the European Union (EU) to the United States (US) in this area; (ii) make NBTXR3 a complementary product to checkpoint inhibitors (iii) complete the post-approval studies of NBTXR3 for the treatment of locally advanced soft tissue sarcomas (STS) in the EU; (iv) to expand the possibilities of NBTXR3 as a treatment for solid tumors; (v) implement an effective clinical development program and establish a global business infrastructure for NBTXR3.
“Following the successful completion of our Nasdaq listing last December, Nanobiotix is poised to continue the global development of the NBTXR3 as planned. Despite the challenges that have arisen in 2020, our team has achieved significant milestones and advanced our development. main product developed in combination with radiotherapy alone or in combination with other anticancer therapies, in several indications. In 2021, we anticipate further advances in the indication of head and neck cancers, which is our priority, and to provide new evidence that NBTXR3 could improve the effects of immunotherapy by increasing the proportion of patients who respond to checkpoint inhibitors.We will also continue within Nanobiotix to expand our development plan to achieve our mission: to enable million patients worldwide benefit from the potential advantages of NBTXR3 “concludes Laurent Levy, President t of the Nanobiotix Board of Directors.
©2021, Boursier.com
–
